Moreover, transcriptomic analyses performed on whole blood samples from advanced melanoma patients treated with ipilimumab (anti-CTLA-4) mAb, showed that the expression of several immunoglobulin genes increased throughout the treatment and that this increase was more prominent in the group of patients exhibiting gastrointestinal irAEs (83). The gene discussed is CTLA4; the disease is melanoma.